These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32926944)

  • 1. When liposomes met antibodies: Drug delivery and beyond.
    Di J; Xie F; Xu Y
    Adv Drug Deliv Rev; 2020; 154-155():151-162. PubMed ID: 32926944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.
    Kesharwani P; Kumari K; Gururani R; Jain S; Sharma S
    Curr Drug Metab; 2022; 23(9):678-692. PubMed ID: 35692131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model.
    Nikpoor AR; Tavakkol-Afshari J; Gholizadeh Z; Sadri K; Babaei MH; Chamani J; Badiee A; Jalali SA; Jaafari MR
    Int J Pharm; 2015 Nov; 495(1):162-170. PubMed ID: 26302860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
    Wang D; Sun Y; Liu Y; Meng F; Lee RJ
    Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of IL-2 conjugated liposomes for therapeutic purposes.
    Konigsberg PJ; Godtel R; Kissel T; Richer LL
    Biochim Biophys Acta; 1998 Mar; 1370(2):243-51. PubMed ID: 9545572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies and associates: Partners in targeted drug delivery.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pros and cons of the liposome platform in cancer drug targeting.
    Gabizon AA; Shmeeda H; Zalipsky S
    J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.
    Koning GA; Morselt HW; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
    Pharm Res; 2001 Sep; 18(9):1291-8. PubMed ID: 11683242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
    Simard P; Leroux JC
    Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding and interstitial penetration of liposomes within avascular tumor spheroids.
    Kostarelos K; Emfietzoglou D; Papakostas A; Yang WH; Ballangrud A; Sgouros G
    Int J Cancer; 2004 Nov; 112(4):713-21. PubMed ID: 15382056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and
    Hua S
    J Liposome Res; 2019 Dec; 29(4):357-367. PubMed ID: 30526169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion molecules: a new target for immunoliposome-mediated drug delivery.
    Bloemen PG; Henricks PA; van Bloois L; van den Tweel MC; Bloem AC; Nijkamp FP; Crommelin DJ; Storm G
    FEBS Lett; 1995 Jan; 357(2):140-4. PubMed ID: 7805880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and developments in liposome drug delivery systems.
    Lian T; Ho RJ
    J Pharm Sci; 2001 Jun; 90(6):667-80. PubMed ID: 11357170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal drug delivery systems: an update review.
    Samad A; Sultana Y; Aqil M
    Curr Drug Deliv; 2007 Oct; 4(4):297-305. PubMed ID: 17979650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoliposomes in clinical oncology: State of the art and future perspectives.
    Merino M; Zalba S; Garrido MJ
    J Control Release; 2018 Apr; 275():162-176. PubMed ID: 29448116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
    Andresen TL; Jensen SS; Jørgensen K
    Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.